KBC Split

The Dermatology Department at KBC Split is conducting studies that test the effectiveness and safety of a novel oral therapy for patients with severe alopecia areata, including both adults and adolescents.

• Assessing rapid regrowth of hair using clinical scoring tools
• Evaluating long‑term safety and tolerability of the treatment
• Optimizing dosing strategies based on patient response

These trials aim to provide new therapeutic options for an autoimmune disease that currently has limited treatments, leveraging the expertise of 28 investigators across five active studies.

Researchers at KBC Split are exploring a targeted agent for patients with active lupus nephritis, a serious manifestation of immune system diseases.

• Investigating proteasome inhibition as a novel mechanism
• Monitoring renal function and disease activity during treatment
• Assessing safety in patients with class III/IV and pure class V disease

The goal is to expand therapeutic options for complex autoimmune conditions, complementing the site’s broader focus on immune‑mediated disorders.